The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults.
Second guideline presents evidence for different biologic agents, including adverse events
Mayne Pharma announced that Lexette (halobetasol propionate) foam 0.05% has been made available for patients 18 years of age and older for the topical treatment of plaque psoriasis.
Noncalcified plaque burden and necrotic core reduced in association with biologic therapy
In order to assess the safety of biologic agents in older patients, the authors utilized PubMed/Medline and Embase to search for studies conducted in older patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis.
In the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, psoriasis patients who reported problems in these quality of life measures (through the EQ-5D-3L questionnaire) were randomized to receive secukinumab 300mg or placebo and were assessed at weeks 4, 8, and 12.
Psoriasis is associated with an increased risk for cardiovascular interventions in patients with hypertension, according to a new study.
Depending on the definition used, there are large variations in the proportion of patients identified as having moderate-to-severe psoriasis.
Using a validated claims-based algorithm, study authors identified pregnancies among women 15-54 years of age from the US Sentinel System between January 1 2004 and September 30 2015.
The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.
